Waldenstrom Macroglobulinemia Clinical Trials

A listing of Waldenstrom Macroglobulinemia medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 57 clinical trials
Featured trial
Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma(CLL/SLL), Lymphoplasmacytic Lymphoma(LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma(SMZL)

(MBL), chronic lymphocytic leukemia(CLL)/small lymphocytic lymphoma (SLL), lymphoplasmacytic lymphoma (LPL)/Waldenstrom macroglobulinemia (WM), and splenic marginal zone lymphoma (SMZL). Applying these

lymphadenopathy
lymphocytosis
waldenstrom's macroglobulinemia
lymphoma
marginal zone lymphoma
  • 115 views
  • 15 Apr, 2019
  • 1 location
Study of Iopofosine I 131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) and Pivotal Expansion in Waldenstrom Macroglobulinemia (CLOVER-WaM)

lymphoma (SLL), lymphoplasmacytic lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), marginal zone lymphoma (MZL), mantle cell lymphoma (MCL), diffuse large B-cell lymphoma (DLBCL), and central nervous

maintenance therapy
anti-cd20 antibody
bone marrow procedure
rituximab
immunotherapeutic agent
  • 735 views
  • 04 Oct, 2022
  • 18 locations
A Phase 2 Study to Evaluate the Efficacy and Safety of MK-1026 in Participants With Hematologic Malignancies

lymphocytic lymphoma (SLL), Richter's transformation, marginal zone lymphoma (MZL), mantle cell lymphoma (MCL), follicular lymphoma (FL), and Waldenström's macroglobulinemia (WM).

measurable disease
lymphoma
mantle cell lymphoma
hepatitis b surface antigen
kinase inhibitor
  • 33 views
  • 28 Oct, 2022
  • 45 locations
A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL

This is an open-label, multi-center Phase 1/2 study of oral LOXO-305 (pirtobrutinib) in patients with CLL/SLL and NHL who have failed or are intolerant to standard of care.

diffuse large b-cell lymphoma
renal function
chronic lymphocytic leukemia refractory
thrombocytopenia
venetoclax
  • 188 views
  • 04 Oct, 2022
  • 59 locations
A Phase 1 Study of Oral LOXO-338, a Selective BCL-2 Inhibitor, in Patients With Advanced Hematologic Malignancies

The purpose of this study is to find out whether the study drug, LOXO-338, is safe and effective in patients with advanced blood cancer. Patients must have already received standard therapy. The study may last up to approximately 3 years.

bone marrow procedure
measurable disease
cancer
  • 0 views
  • 23 Oct, 2022
  • 21 locations
A Phase I, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-523 in Patients With Relapsed or Refractory Lymphoma

This is a Phase I, open-label, multicenter study of HMPL-523 administered orally to patients with relapsed or refractory lymphoma who have exhausted approved therapy options. This study consists of a dose escalation stage (Stage1) and a dose expansion stage (Stage 2).

follicular lymphoma
waldenstrom's macroglobulinemia
marginal zone lymphoma
chronic lymphocytic leukemia
leukemia
  • 0 views
  • 24 Oct, 2022
  • 21 locations
Dasatinib In Waldenström Macroglobulinemia

This is Phase I pilot, single center study designed to explore the safety of Dasatinib in symptomatic Waldenström Macroglobulinemia participants who are progressing on ibrutinib therapy with BTK

platelet count
potassium
ibrutinib
bone marrow procedure
neutrophil count
  • 2 views
  • 05 Apr, 2022
Bendamustine Rituximab and Acalabrutinib in Waldenstrom's Macroglobulinemia

This is a multi-centre, open label, single-arm, phase II clinical trial in untreated patients with Waldenstrom's Macroglobulinemia. Symptomatic, previously untreated patients will receive SOC

monoclonal protein
corticosteroids
lymphoma
bendamustine
rituximab
  • 6 views
  • 04 Aug, 2021
  • 5 locations
R-VRD Followed by Lenalidomide Maintenance in Patients With Waldenstrom's Macroglobulinemia (Ballondor)

A multicenter prospective phase II study of rituximab combined, lenalidomide, dexamethasone followed by lenalidomide maintenance in patients with newly diagnosed Waldenström's macroglobulinemia

lenalidomide
measurable disease
bortezomib
dexamethasone
rituximab
  • 21 views
  • 23 Apr, 2022
  • 1 location
Zanubrutinib Ixazomib and Dexamethasone in Patients With Treatment Naive Waldenstrom's Macroglobulinemia

This study aims to evaluate the efficacy of BTK inhibitor Zanubrutinib combined with Ixazomib and Dexamethasone (ZID) for the newly diagnosed Waldenstrom Macroglobulinemia. This ZID regimen will

lymphoma
neutrophil count
remission
cyclophosphamide
cytopenia
  • 4 views
  • 24 Jan, 2021
  • 1 location